Abbv
Entity.
- Evidence
- 32 documents · 12 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 11 Sept 2026, last seen 26 Oct 2026
- Measured
- 0% of mentions say something specific about it; the rest only name it
- As of
- 26 Oct 2026
Where this comes from
- Ann Oncol · 2026-10-24 · A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with met… (opens the source in a new tab)
- TradingView Ideas · 2026-09-25 · Ascending Triangle Tests Ceiling at 267 for Bullish Continuation (opens the source in a new tab)